Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-02-15

FDA Approved: BENLYSTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for BENLYSTA (belimumab) submitted by GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BENLYSTA (belimumab)

Snippet

SUPPL AP for BENLYSTA (BELIMUMAB)